Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Robbins LLP is Investigating Allegations that Cytokinetics, Inc. (CYTK) Misled Investors About its New Drug Application Submission
-
Robbins LLP announces a class action against Spectrum Pharmaceuticals (SPPI) for alleged securities law violations tied to its cancer drug apaziquone.
-
Robbins LLP is Investigating Allegations that Biohaven Ltd. (BHVN) Misled Investors Regarding the Viability of its Candidates
-
Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug Candidate
-
Robbins LLP is Investigating Allegations that Fortrea Holdings, Inc. (FTRE) Misled Investors Regarding the Progress of its Pre-Spin Projects
-
Robbins LLP is Investigating Allegations that Zenas BioPharma, Inc. (ZBIO) Misled Investors in Connection with its IPO
-
Robbins LLP is Investigating Allegations that Zenas BioPharma, Inc. (ZBIO) Misled Investors in Connection with its IPO
-
Robbins LLP is Investigating Allegations that Geron Corporation (GERN) Misled Investors Regarding the Launch and Potential Growth of Rytelo
-
Robbins LLP is Investigating Allegations that BioAge Labs, Inc. (BIOA) Misled Investors Regarding its Lead Drug Candidate in Connection with its IPO
-
Robbins LLP is Investigating Allegations that BioAge Labs, Inc. (BIOA) Misled Investors Regarding its Lead Drug Candidate in Connection with its IPO